Percutaneous CT-guided radiofrequency ablation for unresectable hepatocellular carcinoma pulmonary metastases

International Journal of Hyperthermia

Volumn 28, Issue 8, 2012, Pages 721-728

  Li, Xishan ^a   Wang, Jianpeng ^b   Li, Wang ^a   Huang, Zilin ^a   Fan, Weijun ^a   Chen, Yumin ^a   Shen, Lijie ^a   Pan, Tao ^a   Wu, Peihong ^a   Zhao, Ming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Prognostic factors; Pulmonary metastases; Radiofrequency ablation; Survival

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOEMBOLIZATION; CHEST TUBE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG METASTASIS; LUNG SURGERY; MALE; MEDICAL RECORD REVIEW; METASTASIS RESECTION; OVERALL SURVIVAL; PAIN; PATIENT SAFETY; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PNEUMOTHORAX; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84869463563     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2012.736669     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, et al. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
3. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012;262:43-58.
4. Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: Present and future. J Gastroenterol Hepatol 2012;27: 862-872.
5. Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, et al. Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors. Cancer 2011;117:4475-4483.
6. Davidson RS, Nwogu CE, Brentjens MJ, Anderson TM. The surgical management of pulmonary metastasis: Current concepts. Surg Oncol 2001;10:35-42. (Pubitemid 33086838)
7. Nichols FC. Pulmonary metastasectomy. Thorac Surg Clin 2012;22:91-99.
8. Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113:37-49. (Pubitemid 27034340)
9. Pastorino U. History of the surgical management of pulmonary metastases and development of the International Registry. Semin Thorac Cardiovasc Surg 2002;14:18-28. (Pubitemid 34467563)
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
11. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
12. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis Bendemic Asian population: Presence of lung metastasis predicts poor response. Cancer 2009;115:428-436.
13. Kim HR, Cheon SH, Lee KH, Ahn JR, Jeung HC, Lee SS, et al. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. Int J Hyperthermia 2010;26:305-315.
14. Pan C, Wu P, Yu J, Li W, Huang Z, He N, et al. CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma. Int J Hyperthermia 2011;27:549-554.
15. Sung HH, Park BK, Kim CK, Choi HY, Lee HM. Comparison of percutaneous radiofrequency ablation and open partial nephrectomy for the treatment of size- and location-matched renal masses. Int J Hyperthermia 2012;28: 227-234.
16. Yamakado K, Inoue Y, Takao M, Takaki H, Nakatsuka A, Uraki J, et al. Long-term results of radiofrequency ablation in colorectal lung metastases: Single center experience. Oncol Rep 2009;22:885-891.
17. Pan CC, Wu PH, Yu JR, Li W, Huang ZL, Wang JP, et al. Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation. Eur J Radiol 2012;81:e473-e477.
18. Soga N, Yamakado K, Gohara H, Takaki H, Hiraki T, Yamada T, et al. Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma. BJU Int 2009;104:790-794.
19. Chua TC, Sarkar A, Saxena A, Glenn D, Zhao J, Morris DL. Long-term outcome of image-guided percutaneous radiofrequency ablation of lung metastases: An open-labeled prospective trial of 148 patients. Ann Oncol 2010;21: 2017-2022.
20. Fernando HC, De Hoyos A, Landreneau RJ, Gilbert S, Gooding WE, Buenaventura PO, et al. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg 2005;129:639-644. (Pubitemid 40311325)
21. Younes RN, Fares AL, Gross JL. Pulmonary metastasectomy: A multivariate analysis of 440 patients undergoing complete resection. Interact Cardiovasc Thorac Surg 2012;14:156-161.
22. Kitano K, Murayama T, Sakamoto M, Nagayama K, Ueno K, Murakawa T, et al. Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg 2012;41:376-382.
23. Gwak GY, Jung JO, Sung SW, Lee HS. Long-term survival after pulmonary metastatectomy of hepatocellular carcinoma: Treatment outcome or natural history? Hepatogastroenterology 2004;51:1428-1433.
24. Kawamura M, Nakajima J, Matsuguma H, Horio H, Miyoshi S, Nakagawa K, et al. Surgical outcomes for pulmonary metastases from hepatocellular carcinoma. Eur J Cardiothorac Surg 2008;34:196-199.
25. Kim TS, Lim HK, Lee KS, Yoon YC, Yi CA, Han D. Imaging-guided percutaneous radiofrequency ablation of pulmonary metastatic nodules caused by hepatocellular carcinoma: Preliminary experience. Am J Roentgenol 2003;181: 491-494. (Pubitemid 36909496)
26. Hiraki T, Yamakado K, Ikeda O, Matsuoka T, Kaminou T, Yamagami T, et al. Percutaneous radiofrequency ablation for pulmonary metastases from hepatocellular carcinoma: Results of a multicenter study in Japan. J Vasc Interv Radiol 2011;22: 741-748.
27. Fernando HC. Radiofrequency ablation to treat non-small cell lung cancer and pulmonary metastases. Ann Thorac Surg 2008;85:S780-S784.
28. Veltri A, Guarnieri T, Gazzera C, Busso M, Solitro F, Fora G, et al. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): Size as the leading prognostic factor for survival. Radiol Med 2012;117:1139-1151.
29. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006;12: 1175-1181.
30. Dupuy DE. Image-guided thermal ablation of lung malignancies. Radiology 2011;260:633-655.
31. Tada A, Hiraki T, Iguchi T, Gobara H, Mimura H, Toyooka S, et al. Influence of radiofrequency ablation of lung cancer on pulmonary function. Cardiovasc Intervent Radiol 2011;35:860-867.
32. Demmy TL, Dunn KB. Surgical and nonsurgical therapy for lung metastasis: Indications and outcomes. Surg Oncol Clin N Am 2007;16:579-605. (Pubitemid 46990948)
33. Jin Y, Cai YC, Cao Y, Cai XY, Tan YT, Shi YX, et al. Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes. J Surg Oncol 2012;106:322-326.
34. Takao M, Yamakado K, Takeda K. Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Cancer 2011;117:876-877.
35. Kashima M, Yamakado K, Takaki H, Kodama H, Yamada T, Uraki J, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: A single center's experiences. Am J Roentgenol 2011;197:W576-W580.
36. Rose SC, Dupuy DE, Gervais DA, Millward SF, Brown DB, Cardella JF, et al. Research reporting standards for percutaneous thermal ablation of lung neoplasms. J Vasc Interv Radiol 2009;20:S474-S485.
37. Purandare NC, Rangarajan V, Shah SA, Sharma AR, Kulkarni SS, Kulkarni AV, et al. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings. Radiographics 2011;31:201-213.